Antiemetic effect

The antiemetic effect is a therapeutic outcome characterized by the prevention or reduction of nausea and vomiting, rather than being a single molecular target or receptor (StatPearls, 2023). This physiological response is mediated by the pharmacological modulation of several distinct signaling pathways within the central nervous system, particularly the chemoreceptor trigger zone (CTZ) in the area postrema and the vomiting center in the medulla, as well as peripheral pathways in the gastrointestinal tract (NIH, 2022). Primary molecular drivers of emesis that serve as drug targets include the 5-hydroxytryptamine 3 (5-HT3) receptor, the neurokinin-1 (NK1) receptor, and the dopamine D2 receptor (NCBI, 2021). Clinically, achieving an antiemetic effect is critical for patients undergoing chemotherapy, recovering from surgery, or suffering from motion sickness (Journal of Clinical Oncology, 2020). Because emesis can be triggered by various stimuli, the specific mechanism of action required to achieve an antiemetic effect often depends on the underlying etiology of the nausea.

Other names

AntiemesisPrevention of nausea and vomitingSuppression of emetic reflexAntinausea action

The antiemetic effect is achieved through the antagonism of specific neurotransmitter receptors involved in the emetic signaling cascade. Key mechanisms include the blockade of 5-HT3 receptors on vagal afferent nerves and in the CTZ, antagonism of NK1 receptors by substance P inhibitors, and the inhibition of dopamine D2 receptors in the area postrema (StatPearls, 2023; NIH, 2022).